Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As I mentioned, we're seeing good underlying demand growth sequentially within the U.S |
| With the exciting approval of Truqap, we have the opportunity to further extend our leadership in breast cancer, including in the hormone receptor positive landscape |
| We believe we can grow, and we believe over the next 10 years we will deliver superior growth |
| And of course, Sharon can talk about that as well makes us quite bullish about this opportunity |
| So my clear star is we are off of a very strong start in the United States |
| Our Phase III cardio transform trial is the largest of its kind and is powered to show a cardiovascular mortality benefit, and we are very pleased to share today that we have obtained Fast Track designation from the FDA for our cardiomyopathy regulatory file |
| And it gives me confidence, we can actually deliver another cycle of very strong growth over the next 10 years |
| As Pascal stated earlier, we've made good progress on both top and bottom line delivery in recent years, and we remain on track to deliver both industry leading growth and improve operating margin to the mid-30s in the midterm |
| Quell's innovative platform of armored T-regs could enable sustained clinical benefit |
| On the EPS front, we grow by 15%, which is also slightly better than upgraded guidance for the year |
| And in the quarter four, we saw an opportunity because we had a tax benefit, we saw an opportunity to invest to drive further growth and stronger growth next year and the years after, as we are launching new products and expanding our footprint, you saw that the emerging markets out of China grew by 35% |
| We can work through the patent expiries that we have that are limited and continue to deliver very strong growth |
| So, China is back again on the growth trajectory, and this year should be another good year |
| We've been improving our operating margin, you see a drop in '21 |
| But I can tell you that we are very, very confident that we can actually grow very strongly over the next few years and work through some of the issues that have been mentioned by some, for instance, Medicare Part reform, we can work through that |
| We have today a huge number of collaborations in the Cambridge area, and this is really leading to very good productivity from our R&D efforts |
| And that's really what we want to show you and hopefully convince you at this R&D day, and I hope many of you will join us in the beautiful disk, where we have tremendously talented teams that are doing a great job |
| And finally, but importantly, we are absolutely confident we can deliver a very strong long-term growth |
| system on the Medicare side, it is going to be a very, very good system |
| And I was really pleased to see and we've been really pleased to see that we've been putting more effort against our promotional efforts within the U.S |
| We believe that this product with every 2-week dosing and lower volume injections, coupled with improved manufacturing creates a significant opportunity to increase the addressable population by 3x as compared to Strensiq |
| And in V&I, Beyfortus continued to see strong demand in its first RSV season, generating $95 million of product sales and alliance revenue for AstraZeneca in the quarter |
| And it's still out there and it's still a very good product with good sales, very good profitability |
| We have a very exciting PCSK9 that is making good progress |
| So as you can see here, quite a lot of new data coming up, both from the Phase III pipeline but also from mid-stage pipeline that will give you a sense for what is coming up and why we believe -- why we are so excited where we believe we can continue to drive top line growth over the next 10 years |
| So the broad utility of the product and no need for a biomarker, no need for phenotyping, makes it a highly attractive choice for especially Alges and more and more pulmonologists as well |
| And drive improvement in profitability as a result of this |
| Our portfolio is doing very well, and all our geographies are doing very, very well |
| This demonstrates the promise of this potential therapy when you move it into an earlier line setting |
| And so what are we trying to do here? First of all, we have -- we believe a tremendous opportunity to leverage our growing pipeline of antibody drug conjugates, with our IO bispecifics |
| Statement |
|---|
| So the guidance, low double-digit or low teens as a revenue target, but I think bears are worried that lots of that is collaboration revenues growing and product sales slowing |
| sales probably were a little bit light in terms of growth of what people were expecting when Daiichi reported them |
| The other is, is that if the data are really compelling, you could see that, that puts some pressure on what we see as a lot of endocrine recycling -- that takes place within these patients |
| The second message is we are committed to this midterm operating margin, and it is, of course, challenging because as you've said, we have a very big portfolio |
| So on the SG&A front, if you look at fourth quarter last year, which I think you mentioned is a concern in terms of the step-up |
| Our full year your core tax rate of 17% came in slightly below our guidance |
| And overall, the net effect is certainly a negative, but it really totally manageable in the context of our total global sales and the growth rate we are experiencing |
| Other operating income, on the other hand is anticipated to decrease substantially |
| We started in a soft way in the last quarter |
| And oftentimes, you see companies not being able to fulfill their growth ambition because of underinvestment in supply |
| The third message maybe is we believe we can manage through the Part D reform, and I mentioned it because I know some people have speculated this is going to be a big problem |
| Having said that, Axis is still, let's say, an issue we are working through |
| But that was a bit of an artifact because it's driven by the very large COVID sales we experienced and of course those who are no profits, so it dilutes operating margin |
| So basically, the headwind that we can anticipate is the introduction of biosimilars in the PNH indication |
| Tim Anderson Thank you, any headwinds to revenue growth for individual key brands in 2024 that you'd like to call out relative to where you see consensus |
| Once again, the biggest change and that's the last question you were asking, what is not the headwind, but what is the biggest challenge? The biggest challenge is we are very happy the 3 large commercial PBMs have now listed as Airsupra but there are multiple downstream PBMs, and we still need to gain access there |
| And again, some of that is at risk, obviously |
| If FX rates for February to December were to remain at average rates seen in 2024 January, we anticipate a low single digit adverse FX impact on both revenue and core EPS in 2024 |
| I mean, headwinds, we have headwinds constantly in 1 market or another, 1 product or another |
| Pascal Soriot So before Aradhana, do you want to take up...? Aradhana Sarin So we talked about the other income, which we expect to decline substantially |
Please consider a small donation if you think this website provides you with relevant information